Imatron expects record 1994 revenues

Article

CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure

CT developer Imatron is anticipating record revenues for its 1994fiscal year (end-December). The South San Francisco, CA, companysaid last week that its revenues for the year should exceed $33million, an increase of at least 31% over last year's figure of$25.1 million. Net income for 1994 should be $2.3 million, versusa loss of $2.9 million in 1993.

Imatron has enjoyed strong sales of its C-150 Ultrafast CTscanner in recent months. Imatron received an order in Decemberfor 10 C-150 units from Imatron Japan in a transaction worth $16million (SCAN 12/28/94). Revenue from that sale will registerin the company's 1995 and 1996 fiscal years.

Imatron's backlog is at its highest level since the companywas formed in 1983, president and CEO Lewis Meyer said. The backlogshould help the firm register revenues of over $40 million in1995.

This year Imatron will embark on a major expansion of its HeartScanImaging clinics, which provide coronary artery screening directlyto the public (SCAN 4/6/94). Imatron plans to open clinics inSeattle, Houston and Washington, DC.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.